3SBio Inc. (HKG:1530)

Market Cap	60.04B
Revenue (ttm)	9.69B
Net Income (ttm)	2.22B
Shares Out	2.36B
EPS (ttm)	0.90
PE Ratio	28.14
Forward PE	23.51
Dividend	0.25 (0.98%)
Ex-Dividend Date	Jul 21, 2025

Volume	42,041,318
Average Volume	49,523,408
Open	25.20
Previous Close	25.15
Day's Range	24.70 - 26.10
52-Week Range	5.47 - 26.10
Beta	0.78
RSI	71.90
Earnings Date	Aug 22, 2025

About 3SBio

3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; and Cipterbin, an anti-HER2 monoclonal antibody for the treatment of advanced HER2-positive breast cancer and pan-HER2. It also offers Yisaipu, the receptor fusion tumor necrosis factor inhibitor; EPIAO and SEPO, an erythropoietin injection; Mandi-minoxidil, an OTC ex...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Employees: 5,577
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1530

Financial Performance

In 2024, 3SBio's revenue was 9.11 billion, an increase of 16.53% compared to the previous year's 7.82 billion. Earnings were 2.09 billion, an increase of 34.93%.

Financial numbers in CNY